The company's most advanced programme is an improved next-generation coagulation Factor VIIa
variant, marzeptacog alfa (activated), that has successfully completed an intravenous Phase 1 clinical trial in individuals with severe hemophilia A or B.
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa
Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa
in patients with severe haemophilia and inhibitors.
LFB has been producing limited amounts of Factor VIIa
in the milk of rabbits in France.
Binding of factor VIIa
to the endothelial cell protein C receptor reduces its coagulant activity.
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa
in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors.
The patient was started on Recombinant Factor VIIa
(Novo Seven) 270mcg/kg followed by 180 mcg/kg every six hours.
Consider off-label treatment with recombinant factor VIIa
only after the patient has received approximately 10 U of packed RBCs and full factor replacement.
More recently, recombinant factor VIIa
has been used investigationally in individuals with a variety of hemorrhagic disorders, including neurologic bleeding.
We recently announced that GTC is focused on achieving key goals related to Factor VIIa
, ATryn(R) and our 'bio-superior' product candidates.
Also in Maxygen's pipeline are a new Factor VIIa
product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis.
Inflammatory cytokines upregulate endothelial expression of tissue factor, the procoagulant protein required for factor VIIa
activity," and down regulate endothelial expression of heparin sulfate/ glycosaminoglycans, the cofactors for the anticoagulant activity of antithrombin.
In this case, the use of recombinant activated factor VIIa
controlled the massive gastrointestinal bleeding secondary to Crohn disease and without clinically significant adverse effect.
Treatment of traumatic bleeding with recombinant factor VIIa
Unchanged global fibrinolytic capacity despite increased factor VIIa
activity in Behcet's disease: evidence of a prethrombotic state.